HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Bender, B. Search for Related Content PubMed Articles by Bender, B. Topic Collections EBM Clinical prediction guide

A simple scoring system predicted clinical progression in HIV patients receiving highly active antiretroviral therapy

The first 150 words of the full text of this article appear below.

Design
Prognostic scoring system developed in 1 derivation cohort and validated in 2 cohorts of patients.

Setting
60 centres in Europe and Israel.

Patients
2027 patients (median age 37 y) formed the derivation set: inception cohort of participants in the EuroSIDA study who were 16 years of age and had started a protease inhibitor or non-nucleoside reverse-transcriptase inhibitor as part of a HAART antiretroviral regimen and had CD4 cell counts and viral loads measured within 6 months before starting HAART and 1 measurement after starting HAART. 2 cohorts of patients formed the validation set: 1946 patients in the EuroSIDA study who started HAART before recruitment to the study and 1442 patients from a clinic in Barcelona who had previously started HAART.

Description of prediction guide
Cox proportional hazards models were used to determine factors associated with clinical progression. The final prediction model comprised the latest CD4 cell count, viral load, haemoglobin concentration, and clinical status at the . . . [Full text of this article]

Bradley Bender, MD

Veterans Affairs Medical Center
Gainesville, Florida, USA